These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 8098065)

  • 1. Beta-blockers in heart failure: potential of carvedilol.
    Fowler MB
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S62-7. PubMed ID: 8098065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Carvedilol].
    Antepohl W; Herzig S; Böhm M
    Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
    [No Abstract]   [Full Text] [Related]  

  • 3. Carvedilol: something else than a simple betablocker?
    Palazzuoli A; Calabria P; Verzuri MS; Auteri A
    Eur Rev Med Pharmacol Sci; 2002; 6(6):115-26. PubMed ID: 12776805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol.
    Frishman WH
    N Engl J Med; 1998 Dec; 339(24):1759-65. PubMed ID: 9845712
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
    Al-Hesayen A; Azevedo ER; Floras JS; Hollingshead S; Lopaschuk GD; Parker JD
    Eur J Heart Fail; 2005 Jun; 7(4):618-23. PubMed ID: 15921803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carvedilol: the new role of beta blockers in congestive heart failure.
    Vanderhoff BT; Ruppel HM; Amsterdam PB
    Am Fam Physician; 1998 Nov; 58(7):1627-34, 1641-2. PubMed ID: 9824960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol for heart failure: renewed interest in beta blockers.
    Young JB
    Cleve Clin J Med; 1997 Sep; 64(8):415-22. PubMed ID: 9308217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
    Feuerstein G; Ruffolo RR
    Adv Pharmacol; 1998; 42():611-5. PubMed ID: 9327976
    [No Abstract]   [Full Text] [Related]  

  • 14. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
    Cleland JG; Charlesworth A; Lubsen J; Swedberg K; Remme WJ; Erhardt L; Di Lenarda A; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson PA;
    J Am Coll Cardiol; 2006 Apr; 47(8):1603-11. PubMed ID: 16630997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers in heart failure: how far have we progressed?
    Adams KF
    Postgrad Med; 2002 Nov; 112(5 Suppl Unanswered):7-15. PubMed ID: 19667603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
    Cheng J; Kamiya K; Kodama I
    Cardiovasc Drug Rev; 2001; 19(2):152-71. PubMed ID: 11484068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of salt intake on the antihypertensive effect of carvedilol.
    Ruilope LM; Lahera V
    J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.